Biotech RadarJobs updated

COMPANY

Gilead

HQ: Foster City, CA source · gilead.com ↗

FDA-approved therapeutic company Clinical Phase 3

433 open jobs · last seen Oct 23, 2026 · 51 sources

Keywords: oncology Pre-Exposure Prophylaxis of HIV Infection HIV-1-infection Non Small Cell Lung Cancer Primary Biliary Cholangitis HIV Infections Hyperuricemia Gout NSCLC Ovarian Cancer Weight Management HER2-negative Gastroesophageal Junction Esophageal Adenocarcinoma Gastric Adenocarcinoma Diabetes Chronic Hepatitis D Infection Type 2 Diabetes Mellitus HNSCC SCLC TNBC - Triple-Negative Breast Cancer CRC Ulcerative Colitis Triple Negative Breast Cancer Pre-Exposure Prophylaxis of HIV-1 Infection Head and Neck Squamous Cell Carcinoma Rheumatoid Arthritis Metastatic Urothelial Cancer HIV Pre-exposure Prophylaxis Chronic Hepatitis Delta Extensive Stage Small Cell Lung Cancer Uterine Endometrial Cancer Endometrial Cancer Advanced Microsatellite Stable Colorectal Cancer MBX-2982 TUB-040 GS-3242 GS-4321 GS-4571

Location: Foster City, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

433+5 patient-care hiddenOpen jobs694Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Medical Director, Clinical Development- Neurology4 locations, including Foster City, California, United StatesOct 22, 2026Oct 9, 2026
Manager, Product AnalystIndia - BengaluruOct 22, 2026Oct 9, 2026
Director, Clinical Development (MD)United States - California - Foster CityOct 22, 2026Oct 9, 2026
Director, Clinical Development (MD)United States - California - Foster CityOct 22, 2026Oct 9, 2026
Quality Control Specialist IIIUnited States - California - La VerneOct 22, 2026Oct 23, 2026

See all 433 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Trial start Phase 2: Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer source ↗
  2. Board tracked Radar started tracking this company’s job board (438 open jobs at last check). source ↗
  3. Trial start Phase 2: Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis source ↗
  4. Trial start Phase 1/Phase 2: Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy source ↗
  5. Trial start Phase 2: Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels source ↗
  6. Trial start Phase 2: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas source ↗
  7. Trial start Phase 2/Phase 3: Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment source ↗
  8. Trial start Phase 1: Study of GS-0415 and How It Works in People With HIV source ↗
  9. Trial start Phase 1: A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors source ↗
  10. Trial start Phase 3: Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy source ↗
  11. Trial start Phase 3: Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens source ↗
  12. Trial start Phase 2: A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 source ↗
  13. Trial start Phase 1: Study of GS-2426 in Participants With Advanced Solid Tumors source ↗
  14. Trial start Phase 2: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer source ↗
  15. Trial start Phase 1/Phase 2: Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer source ↗
  16. Trial start —: Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention source ↗
  17. Trial start Phase 1: Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors source ↗
  18. Trial start Phase 1: Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV source ↗
  19. Trial start Phase 1/Phase 2: Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus source ↗
  20. Trial start Phase 3: Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) source ↗
  21. Trial start Phase 1: Study of GS-0151 in Participants With Rheumatoid Arthritis source ↗
  22. Trial start Phase 3: Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer source ↗
  23. Trial start Phase 2: Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 source ↗
  24. Trial start Phase 1/Phase 2: First in Human Study of TUB-030 in Patients With Advanced Solid Tumors source ↗
  25. Trial start Phase 2/Phase 3: Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 source ↗

Showing 25 of 51 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 433

5 patient-care jobs hidden (phlebotomy, plasma-center, nursing and similar care roles; 438 open jobs in total).

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Medical Director, Clinical Development- Neurology4 locations, including Foster City, California, United StatesOct 22, 2026Oct 9, 2026Senior
Manager, Product AnalystIndia - BengaluruOct 22, 2026Oct 9, 2026Not stated
Director, Clinical Development (MD)United States - California - Foster CityOct 22, 2026Oct 9, 2026Senior
Director, Clinical Development (MD)United States - California - Foster CityOct 22, 2026Oct 9, 2026Senior
Quality Control Specialist IIIUnited States - California - La VerneOct 22, 2026Oct 23, 2026Not stated
Director, Marketing SciencesUnited States - California - Foster CityOct 22, 2026Oct 23, 2026Not stated
Head of Global BenefitsUnited States - California - Foster CityOct 22, 2026Oct 23, 2026Not stated
Sr Director, Business Strategy and OperationsCanada - Alberta - EdmontonOct 22, 2026Oct 23, 2026Not stated
Associate Director, Market Research Integrated Insights, HIV PreventionUnited States - California - Foster CityOct 22, 2026Oct 23, 2026Not stated
Sr Director, Supply Chain2 locations, including Foster City, California, United StatesOct 22, 2026Oct 23, 2026Not stated
Director, Portfolio Digital Capabilities & Innovation, HIV TreatmentUnited States - California - Foster CityOct 22, 2026Oct 23, 2026Not stated
Senior Director, Portfolio Access and Enablement LeadUnited States - California - Foster CityOct 22, 2026Oct 23, 2026Not stated
Associate Director, Portfolio Integration & CommunicationsUnited States - California - Foster CityOct 22, 2026Oct 23, 2026Not stated
IT Commercial Functional LeadIndia - BengaluruOct 22, 2026Oct 23, 2026Not stated
Domain ArchitectIndia - BengaluruOct 22, 2026Oct 23, 2026Not stated
Associate Director - Operations LeadIndia - BengaluruOct 22, 2026Oct 23, 2026Not stated
Manager, IT Support EngineeringIndia - BengaluruOct 22, 2026Oct 23, 2026Not stated
IT Support Engineer IIIndia - BengaluruOct 22, 2026Oct 23, 2026Not stated
Sr Therapeutic Specialist（関西)Japan - TokyoOct 22, 2026Oct 23, 2026Not stated
Senior Medical Scientist Liaison (MSL)- South TexasUnited States - FieldOct 21, 2026Oct 9, 2026Senior
Director, Clinical Development (MD)United States - California - Foster CityOct 21, 2026Oct 9, 2026Senior
Associate Director, Digital Marketing, Data & AI Lead (Ex-US)United Kingdom - UxbridgeOct 21, 2026Oct 9, 2026Senior
Director, Clinical Development (MD)United States - California - Foster CityOct 21, 2026Oct 9, 2026Senior
Senior Director Corporate Development, Search and EvaluationChina - ShanghaiOct 21, 2026Oct 9, 2026Senior
Director, Clinical Development (MD)United States - California - Foster CityOct 21, 2026Oct 9, 2026Senior
Senior Director, Market Access & Reimbursement ItalyItaly - MilanOct 21, 2026Oct 14, 2026Not stated
Senior Director, Gilead Patient Solutions Public AffairsUnited Kingdom - UxbridgeOct 21, 2026Oct 20, 2026Not stated
Senior Manager, Quality AssuranceUnited States - California - Foster CityOct 21, 2026Oct 23, 2026Not stated
Senior Specialist, Quality AssuranceUnited States - California - Foster CityOct 21, 2026Oct 23, 2026Not stated
Manager, Data Science & AI Delivery Lead – Clinical Development and Medical AffairsUnited States - North Carolina - RaleighOct 21, 2026Oct 23, 2026Not stated
Sourcing Director, Commercial Category Management - Foster City, CAUnited States - California - Foster CityOct 21, 2026Oct 23, 2026Not stated
Associate Director, Specialty Laboratory Sourcing, Contracting and Category Management2 locations, including Foster City, California, United StatesOct 21, 2026Oct 23, 2026Not stated
Sr Director, Nonclinical SafetyUnited States – RemoteOct 21, 2026Oct 23, 2026Not stated
Technical TrainerUnited States - Maryland - FrederickOct 21, 2026Oct 23, 2026Not stated
Sr Manager, Clinical Data ManagementUnited States – RemoteOct 21, 2026Oct 23, 2026Not stated
Sr Manufacturing TechUnited States - California - OceansideOct 21, 2026Oct 23, 2026Not stated
Packaging Engineer IIIUnited States - California - Foster CityOct 21, 2026Oct 23, 2026Not stated
Associate Director, Japan Labelling Lead, Regulatory AffairsJapan - TokyoOct 20, 2026Oct 14, 2026Not stated
Director, Commercial Product StrategyUnited Kingdom - UxbridgeOct 20, 2026Oct 20, 2026Not stated
Executive Director, Biostatistics - Medical AffairsUnited States - New Jersey - ParsippanyOct 20, 2026Oct 23, 2026Not stated
Head of Validation - ManufacturingUnited States - California - Foster CityOct 20, 2026Oct 23, 2026Not stated
Vice President, Head of Audit & Risk ManagementUnited States - California - Foster CityOct 20, 2026Oct 23, 2026Not stated
SAP QM End-User Support CoordinatorIreland - CorkOct 19, 2026Oct 9, 2026Mid
Workday Solutions Architect - Talent Management and AIUnited States - California - Foster CityOct 19, 2026Oct 9, 2026Senior
Senior Scientist, Protein TherapeuticsUnited States - California - Foster CityOct 19, 2026Oct 20, 2026Not stated
Senior Cell Therapy Account Manager - East Los Angeles, CA2 locations, including Field, United StatesOct 19, 2026Oct 20, 2026Not stated
Associate Director, End-to-End Commercial Supply Chain Planner2 locations, including Foster City, California, United StatesOct 19, 2026Oct 20, 2026Not stated
Director, Ethics & Compliance Investigations2 locations, including Foster City, California, United StatesOct 19, 2026Oct 20, 2026Not stated
Senior Manager, End-to-End Commercial Supply Planner2 locations, including Foster City, California, United StatesOct 19, 2026Oct 20, 2026Not stated
Aircraft Maintenance LeadUnited States - California - Santa ClaraOct 19, 2026Oct 20, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 433 jobs →

Clinical trials (lead sponsor) Showing 50 of 694

RecordTitlePhaseStatusStartPrimary completion
NCT06562907Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)Phase 1RecruitingAug 28, 20242027-02 (estimated)
NCT06051617Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPhase 3RecruitingSep 7, 20232030-08 (estimated)
NCT04925752Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionPhase 3Active, not recruitingJun 28, 2021Aug 21, 2024 (actual)
NCT07473778Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNot listedRecruitingMar 17, 20262028-04 (estimated)
NCT04150068Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug ResistancePhase 2/Phase 3Active, not recruitingNov 21, 2019Oct 5, 2020 (actual)
NCT06532656Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1Phase 2/Phase 3Active, not recruitingNov 20, 20242030-07 (estimated)
NCT07841990Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsPhase 2Not yet recruiting2026-092027-08 (estimated)
NCT07841977Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisPhase 2Not yet recruiting2026-102028-06 (estimated)
NCT02881320Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1Phase 2/Phase 3Active, not recruitingSep 21, 2016Mar 24, 2025 (actual)
NCT07719491Study of GS-0415 and How It Works in People With HIVPhase 1RecruitingJul 22, 20262029-08 (estimated)
NCT07546812Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasPhase 2RecruitingAug 7, 20262030-01 (estimated)
NCT01336686Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With GoutPhase 2Completed2011-052011-11 (actual)
NCT02252835Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutPhase 2Completed2014-082014-12 (actual)
NCT01035879Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 DiabetesPhase 2Completed2009-122010-08 (actual)
NCT05718700Study of Bulevirtide in Participants With Chronic Hepatitis D InfectionNot listedTerminatedFeb 7, 2023Aug 31, 2026 (actual)
NCT00814372Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on MetforminPhase 2Terminated2008-122010-02 (actual)
NCT05007782Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsPhase 1Active, not recruitingAug 18, 20212028-12 (estimated)
NCT07806773Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung CancerPhase 2Not yet recruiting2026-112029-05 (estimated)
NCT06303505FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCPhase 1/Phase 2RecruitingJun 12, 20242027-12 (estimated)
NCT06657222First in Human Study of TUB-030 in Patients With Advanced Solid TumorsPhase 1/Phase 2RecruitingDec 13, 20242028-12 (estimated)
NCT06029972Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisPhase 2Active, not recruitingDec 5, 20232027-01 (estimated)
NCT05186974Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)Phase 2Active, not recruitingMay 30, 20222027-03 (estimated)
NCT06337032A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsPhase 4RecruitingAug 27, 20242034-03 (estimated)
NCT05633654Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3RecruitingDec 12, 20222027-06 (estimated)
NCT07708727Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentPhase 2/Phase 3RecruitingJul 29, 20262030-10 (estimated)
NCT02842086Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 InfectionPhase 3TerminatedSep 2, 2016Jan 31, 2019 (actual)
NCT07703878A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid TumorsPhase 1RecruitingJul 17, 20262029-09 (estimated)
NCT07645287A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Phase 2RecruitingJun 15, 20262027-08 (estimated)
NCT06727565Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Phase 2Active, not recruitingFeb 18, 20252027-03 (estimated)
NCT06902519Study of GS-0151 in Participants With Rheumatoid ArthritisPhase 1Active, not recruitingMay 14, 20252027-03 (estimated)
NCT03547973Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadPhase 2Active, not recruitingAug 13, 20182030-04 (estimated)
NCT07736937Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian CancerPhase 1/Phase 2RecruitingMar 30, 20262028-03 (estimated)
NCT07047716Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)Phase 3Active, not recruitingJul 22, 20252028-09 (estimated)
NCT07096193Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusPhase 1/Phase 2RecruitingJul 31, 20252030-01 (estimated)
NCT07055451Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVPhase 1Active, not recruitingAug 12, 20252028-03 (estimated)
NCT07128303Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsPhase 1RecruitingAug 28, 20252028-05 (estimated)
NCT06101329Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)Phase 2Active, not recruitingNov 17, 2023Jul 22, 2026 (actual)
NCT07682961Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPhase 3RecruitingJul 14, 20262029-03 (estimated)
NCT06101342Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)Phase 2Active, not recruitingDec 13, 2023Jul 27, 2026 (actual)
NCT06167317Study of GS-0201 Alone and in Combination in Participants With Advanced Solid TumorsPhase 1RecruitingJan 9, 20242028-09 (estimated)
NCT06801834Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerPhase 3RecruitingApr 4, 20252029-10 (estimated)
NCT05502341Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenPhase 2/Phase 3Active, not recruitingAug 16, 2022Sep 29, 2025 (actual)
NCT04994509Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPhase 3Active, not recruitingAug 30, 2021May 27, 2024 (actual)
NCT07743541Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune TherapyPhase 1/Phase 2Not yet recruiting2026-102029-09 (estimated)
NCT07601243Study of GS-2426 in Participants With Advanced Solid TumorsPhase 1RecruitingJun 2, 20262029-01 (estimated)
NCT07683000Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensPhase 3RecruitingJul 14, 20262029-03 (estimated)
NCT06486441Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)Phase 3Active, not recruitingAug 28, 20242029-06 (estimated)
NCT07527858Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerPhase 2RecruitingMay 19, 20262028-12 (estimated)
NCT05840224Study of GS-4528 in Adults With Solid TumorsPhase 1Active, not recruitingMay 11, 20232026-10 (estimated)
NCT05006794Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid MalignanciesPhase 1TerminatedSep 15, 2021Jun 16, 2025 (actual)

Connect

See your connections at Gilead on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback